Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
Silke Gillessen(Institute of Oncology Research), Ken Herrmann(Essen University Hospital), Kim N.(Asian Institute of Technology), Eric J. Small(CancerCare Manitoba), Karim Fizazi(Université de Lille), Pierre Blanchard(Inserm), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Anders Bjartell(Lund University), Emmanuel S. Antonarakis(University of Minnesota), Felix Y. Feng(University of Michigan), Bertrand Tombal(Cliniques Universitaires Saint-Luc), Robert G. Bristow(Princess Margaret Cancer Centre), Ana M. Aparicio(The University of Texas MD Anderson Cancer Center), Nicholas D. James(Royal Marsden NHS Foundation Trust), Daniel Castellano(Universidad Complutense de Madrid), Orazio Caffo(Ospedale Santa Chiara), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Ignacio Durán(Instituto de Biomedicina de Sevilla), Andrew J. Armstrong(Duke University), Heather H. Cheng(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Daniel J. George(Duke University), Himisha Beltran(Dana-Farber Cancer Institute), Gedske Daugaard(Copenhagen University Hospital), Tomasz M. Beer(Exact Sciences (United States)), Jason A. Efstathiou(Massachusetts General Hospital), Caroline S. Clarke(The Royal Free Hospital), Susan Halabi(Duke Medical Center), Nicolas Mottet(Centre Hospitalier Universitaire de Saint-Étienne), Valérie Fonteyne(Ghent University Hospital), Stefano Fanti(Azienda USL di Bologna), Muhammad Bulbul(American University of Beirut Medical Center), Martin Gleave(University of British Columbia), Ian D. Davis(Austin Health), Noel W. Clarke(The Christie NHS Foundation Trust), Mark Frydenberg(Monash University), Gwénaëlle Gravis(Centre National de la Recherche Scientifique), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Elena Castro(Research Institute Hospital 12 de Octubre), Nicola Fossati(Ospedale regionale di Lugano), Eleni Efstathiou(The University of Texas MD Anderson Cancer Center), Neal D. Shore(Carolina Urologic Research Center), Christopher P. Evans(University of Nevada, Reno), Matthew R. Smith(Massachusetts General Hospital), Alberto Bossi(Institut Gustave Roussy), Maria De Santis(Medical University of Vienna), Daniel Heinrich(San Antonio College), Onyeanunam Ngozi Ekeke(University of Port Harcourt Teaching Hospital), Gerhardt Attard(London Cancer), Simon Chowdhury(Sarah Cannon Research Institute), Christopher J. Sweeney(The University of Adelaide)
Cited by 122
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k